about
Dendritic cell immunoreceptor is a new target for anti-AIDS drug development: identification of DCIR/HIV-1 inhibitorsComputational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder.DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compoundsAn integrated map of HIV-human protein complexes that facilitate viral infection.Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.Recent advances in antiretroviral drugs.Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor.Zinc finger proteins as templates for metal ion exchange and ligand reactivity. Chemical and biological consequences.Au(iii) compounds as HIV nucleocapsid protein (NCp7)-nucleic acid antagonists.Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.Short communication: adhesion pathways utilized by HIV-infected lymphocytes.Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir.Interview: Nanomedicine and the fight against HIV/AIDS.Current Strategies for Inhibition of Chikungunya Infection.
P2860
Q28534580-1B7B649D-E02A-4A8B-802B-8BB5A72AFD38Q34854675-ACE17410-43B2-4FD1-935A-14B5954B897FQ34879200-524E2579-8467-49FF-8ABD-C71CD14D15E2Q35052848-E83EA01E-DB71-45A8-BB9B-070F7466DCECQ35166692-174EC828-4791-4D59-864F-281D231BB442Q35746131-983A07C3-5912-44B3-A917-0D0C9B93053BQ35866029-EDA16325-EFDE-47FA-9263-F1844DF7520FQ36102542-1A4E5D72-8623-42D8-9295-D8D022E715A3Q37779092-500A916C-2932-47A3-AAB4-3F0DD01B926FQ37812614-64F2A680-EEC5-401A-BA55-20D806A4A9D0Q37831171-D31CCE73-BFD8-4C82-8A82-7511090ED896Q40470728-B3C8BA6F-462A-4137-82B9-E627D1458116Q41870119-AA310695-17BD-4EF3-940A-9B5EA520576AQ42348446-219E6788-5C86-4C86-B784-79CF57B56F94Q45096179-E2162EE6-28CD-4C47-9C85-0F8DC3E71B00Q45722674-D5E4133F-A354-465C-81A0-9C0951491D9DQ48375952-9F38DEF7-F7DD-435C-ACD8-79E4FAC26728Q54214355-3E9E3203-161C-4296-ADF1-AF97C402F931
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel targets for anti-retroviral therapy.
@en
Novel targets for anti-retroviral therapy.
@nl
type
label
Novel targets for anti-retroviral therapy.
@en
Novel targets for anti-retroviral therapy.
@nl
prefLabel
Novel targets for anti-retroviral therapy.
@en
Novel targets for anti-retroviral therapy.
@nl
P1433
P1476
Novel targets for anti-retroviral therapy.
@en
P2093
Husam Osman
Sanjay Bhattacharya
P304
P356
10.1016/J.JINF.2009.09.014
P577
2009-10-06T00:00:00Z